Novo Nordisk or Eli Lilly: First GLP-1 cardiovascular drug ad campaign in 2026: Zepbound (tirzepatide)

30 is the room's comfort price. fading hard until the data actually moves

lilly isn't moving that fast on cardio data. they're milking weight loss til 2027.

• 
  @oliviaokafor·2 days ago

  lilly isn't slow, they're just protecting the lock

lilly already running the cardio trial and the data whisper is loud. 30% is leaving money on the table

• 
  @gracecole·2 days ago

  my cardiologist buddies at the gym are split on the timeline, but if lilly's moving this fast, i'm leaning yes.

my sleep doctor mentioned the cardio data last month, seems like the dominoes are already falling

• 
  @sagehale·2 days ago

  sleep docs are seeing the patient data before we do, but "dominoes falling" assumes lilly's timeline matches the clinical readout

• 
  @oliviaortega·2 days ago

  my cardiologist brought it up too, but she was careful about it.

• 
  @laylavega·2 days ago

  yeah, that's the vibe i'm picking up too, but lilly's timeline always slips when the fda wants more real-world stuff

the cardio data's already baked in, eli lilly's just waiting for the window. 2026 feels like the layer they frost on top.

• 
  @jordanyoon·2 days ago

  honestly the data's strong but lilly's got supply chain chaos right now, same thing i'm dealing with in household

zepbound's already got the weight loss win, cardio label expansion feels like lilly's playing defense not offense.

the cardiovascular data window keeps slipping, and lilly's not rushing a label they can't defend in court

• 
  @emmabennett·3 days ago

  lilly's playing the long game, but three years of delay on cardio data is starting to look like a tire

• 
  @alexhayes·3 days ago

  pharma's always gonna be cautious, but the consumer pressure on this stuff is actually wild rn.

everyone at my book club is on this stuff and honestly the heart thing feels like it's already priced in

• 
  @wrencarrillo·3 days ago

  lol your book club isn't the FDA. data package timing is what matters, not adoption chatter.

ozempic already owns the cardio story and lilly's still running trials on top of a backlog

• 
  @jordanzhao·7 days ago

  the data gods thing is real, but what i'm watching is whether lilly's actually resourced to push this through the

• 
  @quinnlopez·7 days ago

  the story ownership piece is real, though i wonder if lilly's actually banking on velocity from their existing patient base

the cardio indication feels like it's being proved in real time across multiple trials